MLYS
NASDAQ
US
Mineralys Therapeutics, Inc. - Common Stock
$26.97
▲ +$0.56
(+2.12%)
Vol 1.6M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.9B
ROE
-48.2%
D/E
0.00
Beta
0.32
52W
$8–$48
Wall Street Consensus
15 analysts · Apr 20265
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
86.7%
Buy Rating
Price Chart
Similar Stocks
IMNM
Immunome Inc
$2.4B
SRPT
Sarepta Therapeutics Inc
$2.3B
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $-0.47
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.47 | — | — |
| Dec 2025 | $-0.54 | $-0.40 | +$0.14 |
| Sep 2025 | $-0.63 | $-0.52 | +$0.11 |
| Jun 2025 | $-0.73 | $-0.66 | +$0.07 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -70.4% | -70.4% | -70.4% | -70.4% | -48.2% | -48.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 15.12 | 15.12 | 15.12 | 15.12 | 25.50 | 25.50 |
Key Ratios
ROA (TTM)
-45.8%
P/B
3.2
EPS (TTM)
$-2.96
CF/Share
$-1.21
52W High
$47.65
52W Low
$8.24
$8.24
52-Week Range
$47.65
How does MLYS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
MLYS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
3.2
▲
30%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
MLYS profitability vs Biotechnology peers
ROE
-48.2%
▲
28%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-45.8%
▲
2%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
MLYS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
25.5
▲
474%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
67%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
MLYS fundamentals radar
MLYS
Peer median
Industry
MLYS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio